Ryvu Therapeutics S.A. (WSE:RVU)

Market Cap	552.57M +5.8%
Revenue (ttm)	87.70M -14.0%
Net Income	-101.23M
EPS	-4.38
Shares Out	23.12M
PE Ratio	n/a
Forward PE	8.93
Dividend	n/a
Ex-Dividend Date	n/a

Volume	18,476
Average Volume	35,043
Open	23.50
Previous Close	23.55
Day's Range	23.25 - 23.90
52-Week Range	20.50 - 36.00
Beta	0.59
RSI	49.07
Earnings Date	May 21, 2026

About Ryvu Therapeutics

Ryvu Therapeutics S.A., a clinical-stage drug discovery and development company, engages in developing of small molecule therapies for treatment in oncology in Poland, European Union, and internationally. The company’s lead candidate, Romaciclib (RVU120), is a CDK8 and CDK19 kinase inhibitor in Phase 2 clinical trial with potential to treat monotheraphy, combination therapy, monotherapy, and myelofibrosis. It also develops Dapolsertib (SEL24/MEN1703), a dual PIM and FLT3 kinase inhibitor licensed to the Menarini Group that is in study start-up ...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2007
• Employees: 228
• Stock Exchange: Warsaw Stock Exchange
• Ticker Symbol: RVU

Financial Performance

In 2025, Ryvu Therapeutics's revenue was 87.70 million, a decrease of -13.98% compared to the previous year's 101.96 million. Losses were -101.23 million, -9.16% less than in 2024.